Roanna Ruiz
Stock Analyst at Leerink Partners
(0.82)
# 3,837
Out of 4,944 analysts
63
Total ratings
33.33%
Success rate
-16.09%
Average return
Main Sectors:
Stocks Rated by Roanna Ruiz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKBA Akebia Therapeutics | Initiates: Outperform | $7 | $3.32 | +110.84% | 1 | Apr 28, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $5 → $6 | $7.30 | -17.81% | 5 | Mar 7, 2025 | |
| CRMD CorMedix | Initiates: Outperform | $18 | $11.50 | +56.52% | 1 | Mar 7, 2025 | |
| LXRX Lexicon Pharmaceuticals | Downgrades: Market Perform | $1 | $1.06 | -5.66% | 1 | Mar 4, 2025 | |
| VIR Vir Biotechnology | Maintains: Outperform | $18 → $20 | $4.36 | +359.24% | 4 | Jan 13, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Outperform | $26 → $27 | $16.66 | +62.06% | 4 | Jan 13, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $12 → $13 | $3.78 | +243.92% | 3 | Oct 25, 2024 | |
| ARDX Ardelyx | Initiates: Outperform | $14 | $5.60 | +150.00% | 1 | Apr 5, 2024 | |
| UTHR United Therapeutics | Initiates: Outperform | $330 | $301.39 | +9.49% | 1 | Feb 5, 2024 | |
| CYTK Cytokinetics | Initiates: Outperform | $58 | $34.31 | +69.05% | 1 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $25 | $73.59 | -66.03% | 1 | Apr 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | $49 | $6.85 | +615.33% | 10 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $13 | $4.80 | +170.83% | 7 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $6 | $3.51 | +70.94% | 6 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $25.00 | -24.00% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $120 | $53.90 | +122.63% | 3 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $75 → $50 | $7.44 | +572.49% | 7 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $40 | $14.88 | +168.82% | 6 | Oct 19, 2022 |
Akebia Therapeutics
Apr 28, 2025
Initiates: Outperform
Price Target: $7
Current: $3.32
Upside: +110.84%
Xeris Biopharma Holdings
Mar 7, 2025
Maintains: Outperform
Price Target: $5 → $6
Current: $7.30
Upside: -17.81%
CorMedix
Mar 7, 2025
Initiates: Outperform
Price Target: $18
Current: $11.50
Upside: +56.52%
Lexicon Pharmaceuticals
Mar 4, 2025
Downgrades: Market Perform
Price Target: $1
Current: $1.06
Upside: -5.66%
Vir Biotechnology
Jan 13, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $4.36
Upside: +359.24%
ARS Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $16.66
Upside: +62.06%
Aquestive Therapeutics
Oct 25, 2024
Maintains: Outperform
Price Target: $12 → $13
Current: $3.78
Upside: +243.92%
Ardelyx
Apr 5, 2024
Initiates: Outperform
Price Target: $14
Current: $5.60
Upside: +150.00%
United Therapeutics
Feb 5, 2024
Initiates: Outperform
Price Target: $330
Current: $301.39
Upside: +9.49%
Cytokinetics
Aug 15, 2023
Initiates: Outperform
Price Target: $58
Current: $34.31
Upside: +69.05%
Apr 11, 2023
Initiates: Market Perform
Price Target: $25
Current: $73.59
Upside: -66.03%
Feb 9, 2023
Reiterates: Market Perform
Price Target: $49
Current: $6.85
Upside: +615.33%
Jan 27, 2023
Maintains: Outperform
Price Target: $12 → $13
Current: $4.80
Upside: +170.83%
Jan 27, 2023
Maintains: Market Perform
Price Target: $8 → $6
Current: $3.51
Upside: +70.94%
Dec 20, 2022
Initiates: Outperform
Price Target: $19
Current: $25.00
Upside: -24.00%
Nov 15, 2022
Maintains: Outperform
Price Target: $110 → $120
Current: $53.90
Upside: +122.63%
Nov 3, 2022
Maintains: Market Perform
Price Target: $75 → $50
Current: $7.44
Upside: +572.49%
Oct 19, 2022
Maintains: Market Perform
Price Target: $60 → $40
Current: $14.88
Upside: +168.82%